4.4 Article

Increased mortality and morbidity in mild primary hyperparathyroid patients The Parathyroid Epidemiology and Audit Research Study (PEARS)

期刊

CLINICAL ENDOCRINOLOGY
卷 73, 期 1, 页码 30-34

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1365-2265.2009.03766.x

关键词

-

资金

  1. Chief Scientist Office in Scotland
  2. Chief Scientist's Office, Scotland, UK
  3. Amgen, Australia
  4. Pfizer
  5. GSK
  6. Novartis
  7. Amgen
  8. Chief Scientist Office [CZH/4/395] Funding Source: researchfish

向作者/读者索取更多资源

Objective To describe mortality and disease-specific morbidities in patients with mild primary hyperparathyroidism (PHPT). Design Retrospective population-based observational study. Setting Tayside, Scotland, from 1997 to 2006. Participants Patients with mild PHPT were selected from a pre-defined PHPT cohort between 1997 and 2006. Main outcome measures Standardised mortality ratios (SMRs) were examined for all-cause mortality, as well as cardiovascular and cancer mortality. Standardised morbidity ratios and standardised incidence ratios were also calculated for eleven observed co-morbidities. Results In total, there were 1683 (69 1% female) patients identified with mild PHPT in Tayside. Patients were found to have an increased risk of all-cause mortality and cardiovascular mortality (SMR-all cause 2 62, 95% CI 2.39-2.86; SMR-cardiovascular 2.68, 95% CI 2.34-3.05). Patients with mild PHPT had a significantly increased risk of developing cardiovascular and cerebrovascular disease, renal dysfunction and fractures compared to the age- and sex-adjusted general population. Conclusions Mortality and morbidity were increased for patients with mild untreated PHPT, which is similar to more severe PHPT.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据